Anavex Life Sciences Corp (AVXL)

[JB3729]

The PR on August 12, 2015 revealing the Notice of Allowance for U.S. patent application related to A2-73 stated this (bold by me)-

The allowed patent claims cover formulations and treatments that provide particular coverage relating to improved sigma receptor ligands and their use.

“This patent is a valuable addition to our IP portfolio and covers innovations we have made in our development efforts for ANAVEX 2-73 and beyond,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We have filed numerous patent applications to cover promising compositions and therapies, including those pertaining to ANAVEX 2-73, in keeping with our commitment to a comprehensive IP protection strategy.”

Additional U.S. patent applications filed for pharmaceutical composition of matter for ANAVEX 2-73 will, if granted, provide further patent protection until at least 2035. An additional patent application on file for ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil, if granted, will provide protection for composition of matter until at least 2033.

Wouldn't it be likely that Anavex has filed an updated A2-73 patent application covering Alzheimer's based on "improved sigma receptor ligands and their use" and "innovations we have made in our development efforts for ANAVEX 2-73".